Literature DB >> 18359424

Utility of Gram stain in the clinical management of suspected ventilator-associated pneumonia. Secondary analysis of a multicenter randomized trial.

M Albert1, J O Friedrich, N K J Adhikari, A G Day, C Verdant, Daren K Heyland.   

Abstract

PURPOSE: Gram stains of endotracheal aspirates (EA) and bronchoalveolar lavages (BAL) may guide empiric antibiotic therapy in critically ill patients with suspected ventilator-associated pneumonia (VAP). Previous studies differ regarding the ability of the Gram stain to predict final culture results. The aim of the present study was to evaluate the relationship between EA or BAL Gram stains and final culture results in intensive care unit patients with a suspected VAP.
MATERIAL AND METHODS: We retrospectively analyzed data from the Canadian multicenter VAP study to correlate EA or BAL Gram stain and final culture results. We categorized Gram stains as Gram positive (GP) and Gram negative (GN) if any GP or GN organisms respectively were seen on staining. Cultures were considered "positive" if they yielded pathogenic organisms on final results.
RESULTS: Seven hundred forty patients were enrolled in the study; 35 did not have a Gram stain done leaving 350 BALs and 355 EAs from 705 patients. Pooling BAL and EA results, we found the overall agreement between Gram stain class and pathogenic bacteria culture results to be poor (kappa = 0.36; 95% CI, 0.31-0.40). Among specimens with Gram stains showing no organisms, 99 (30%) of 331 grew pathogenic organisms. Among specimens with Gram stains showing no GN organisms, 113 (25%) of 452 grew pathogenic GN organisms. Among specimens with Gram stains showing no GP organisms, 45 (11%) of 428 grew pathogenic GP organisms.
CONCLUSIONS: Gram stains performed for clinically suspected VAP poorly predict the final culture result and thus have a limited role in guiding initial empiric antibiotic therapy in such patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18359424     DOI: 10.1016/j.jcrc.2008.01.004

Source DB:  PubMed          Journal:  J Crit Care        ISSN: 0883-9441            Impact factor:   3.425


  4 in total

1.  Potentiation effects of amikacin and fosfomycin against selected amikacin-nonsusceptible Gram-negative respiratory tract pathogens.

Authors:  A Bruce Montgomery; Paul R Rhomberg; Tammy Abuan; Kathie-Anne Walters; Robert K Flamm
Journal:  Antimicrob Agents Chemother       Date:  2014-04-21       Impact factor: 5.191

2.  Amikacin-fosfomycin at a five-to-two ratio: characterization of mutation rates in microbial strains causing ventilator-associated pneumonia and interactions with commonly used antibiotics.

Authors:  A Bruce Montgomery; Paul R Rhomberg; Tammy Abuan; Kathie-Anne Walters; Robert K Flamm
Journal:  Antimicrob Agents Chemother       Date:  2014-04-21       Impact factor: 5.191

3.  Systematic review of studies investigating ventilator associated pneumonia diagnostics in intensive care.

Authors:  Basem Al-Omari; Peter McMeekin; A Joy Allen; Ahsan R Akram; Sara Graziadio; Jana Suklan; William S Jones; B Clare Lendrem; Amanda Winter; Milo Cullinan; Joanne Gray; Kevin Dhaliwal; Timothy S Walsh; Thomas H Craven
Journal:  BMC Pulm Med       Date:  2021-06-09       Impact factor: 3.317

4.  Evaluation of semi-quantitative scoring of Gram staining or semi-quantitative culture for the diagnosis of ventilator-associated pneumonia: a retrospective comparison with quantitative culture.

Authors:  Soshi Hashimoto; Nobuaki Shime
Journal:  J Intensive Care       Date:  2013-10-23
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.